AFINITOR DISPERZ 2 MG
EVEROLIMUS : 2 MG · DIN 02425645 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is AFINITOR DISPERZ?
AFINITOR DISPERZ 2 MG contains EVEROLIMUS : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02425645, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Nov-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AFINITOR DISPERZ used for?
AFINITOR (everolimus) is indicated for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole. It is also indicated for the treatment of well- or moderately differentiated neuroendocrine tumours of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease that has progressed within the last 12 months. Additionally, AFINITOR is indicated for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease. AFINITOR is indicated for the treatment of patients with metastatic renal cell carcinoma (RCC) of clear cell morphology, after failure of initial treatment with either of the vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF-receptor TKIs) sunitinib or sorafenib. AFINITOR and AFINITOR DISPERZ are indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that have demonstrated serial growth, who are not candidates for surgical resection and for whom immediate surgical intervention is not required. AFINITOR DISPERZ is indicated as adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC) in patients 2 years and older, with a definite diagnosis of TSC, who are not satisfactorily controlled with current therapies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02425645 |
|---|---|
| Brand name | AFINITOR DISPERZ |
| Generic / active ingredient | EVEROLIMUS : 2 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 2 MG |
| Dosage form | TABLET FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AH02 EVEROLIMUS |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Nov-2014 |
| Original market date | 2014-11-28 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code L04AH02 EVEROLIMUS. 21 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AFINITOR | 10 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02339528 |
| AFINITOR | 2.5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02369257 |
| AFINITOR | 5 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02339501 |
| AFINITOR DISPERZ | 3 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02425653 |
| AFINITOR DISPERZ | 5 MG | TABLET FOR SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02425661 |
| NAT-EVEROLIMUS | 10 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530120 |
| NAT-EVEROLIMUS | 2.5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530090 |
| NAT-EVEROLIMUS | 5 MG | TABLET | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02530104 |
| PMS-EVEROLIMUS | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02504693 |
| PMS-EVEROLIMUS | 2.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02504677 |
Who else supplies EVEROLIMUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EVEROLIMUS appears in 433 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.